Case Reports
17 June 2025
Early Access
https://doi.org/10.4081/itjm.2025.2019

A case report of bladder cancer-related acquired hemophilia A

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Acquired hemophilia A, bladder tumor, bleeding risk, factor VIII inhibitors
11
Views
8
Downloads

Authors

Gaia Dragoni
https://orcid.org/0009-0007-6332-0641
Division of Clinical Medicine, Department of Medicine and Surgery, University of Parma, Italy.
Nicolò Ferraroni
https://orcid.org/0009-0009-9432-5722
Division of Clinical Medicine, Department of Medicine and Surgery, University of Parma, Italy.
Raffaella Benedetti
Internal Medicine Unit, Medical Department, Hemostasis and Thrombosis Center, Hospital of Piacenza, Italy.
Aderville Cabassi
Division of Clinical Medicine, Department of Medicine and Surgery, University of Parma, Italy.
Davide Imberti
d.imberti@ausl.pc.it
Internal Medicine Unit, Medical Department, Hemostasis and Thrombosis Center, Hospital of Piacenza, Italy.

Acquired hemophilia A (AHA) is an extremely rare (incidence of 1.5/1,000,000) and potentially life-threatening disorder characterized by the production of autoantibodies against coagulation factor VIII with a consequent increased bleeding risk; it mainly affects elderly people, and approximately 6-22% of the cases are cancer-related. We report the case of an 84-year-old man who presented with subcutaneous hematomas and anemia; he had prolonged activated partial thromboplastin time, coagulation factor VIII deficiency, and high levels of factor VIII antibodies, and he was successfully treated with prednisone, cyclophosphamide, and recombinant activated factor VII as a bypassing agent.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Huth-Kuhne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009;94:566-75. DOI: https://doi.org/10.3324/haematol.2008.001743
Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007;109:1870-7. DOI: https://doi.org/10.1182/blood-2006-06-029850
Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015;125:1091-7. DOI: https://doi.org/10.1182/blood-2014-07-587089
Collins P, Baudo F, Huth-Kühne A, et al. Consensus recommendations for the diagnosis and treatment of acquired haemophilia A. BMC Res Notes 2010;3:161. DOI: https://doi.org/10.1186/1756-0500-3-161
Napolitano M, Siragusa S, Mancuso S, Kessler CM. Acquired haemophilia in cancer: a systematic and critical literature review. Haemophilia 2018;24:43-56. DOI: https://doi.org/10.1111/hae.13355
Ryšánková K, Gumulec J, Grepl M, Krhut J. Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: a case report. World J Clin Cases 2023;11:5338-43. DOI: https://doi.org/10.12998/wjcc.v11.i22.5338
Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012;120:47-5. DOI: https://doi.org/10.1182/blood-2012-02-409185
Tiede A, Collins P, Koeb P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia. Haematologica 2020;105:1791-801. DOI: https://doi.org/10.3324/haematol.2019.230771
Kreuter M, Retzlaff S, Enser-Weis U, et al. Acquired haemophilia in a patient with gram-negative urosepsis and bladder cancer. Haemophilia 2005;11:181-5. DOI: https://doi.org/10.1111/j.1365-2516.2005.01066.x
Taza F, Suleman N, Paz R, Haas C. Acquired hemophilia A and urothelial carcinoma. J Community Hosp Intern Med Perspect 2021;11:89-93. DOI: https://doi.org/10.1080/20009666.2020.1836726
Onitilo AA, Skorupa A, Lal A, Ronish E et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006;96:84-7. DOI: https://doi.org/10.1160/TH06-03-0183
Tiede A, Worster A. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol 2018;97:1889-901. DOI: https://doi.org/10.1007/s00277-018-3372-z

How to Cite



A case report of bladder cancer-related acquired hemophilia A. (2025). Italian Journal of Medicine. https://doi.org/10.4081/itjm.2025.2019
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.